Biotech & Pharma
Health Tech
Business & Policy
Health & Science
Team
Exclusive analysis of biotech, pharma, and the life sciences
Topics
Columns
Tools
Events
Team
Account
More
Follow Us
In-depth analysis of biotech, pharma, and the life sciences
from some of the nation's most trusted and well-connected reporters in the industry
with STAT+ reporters and leading industry experts in our STAT+ Conversations series
hosted by STAT+, plus early-bird access and discounts to industry events around the country
get delivered to your inbox to brief you on the most important industry news of the day
like our CRISPR Trackr and Drug Pricing Policy Tracker
In-depth analysis of biotech, pharma, and the life sciences
from some of the nation's most trusted and well-connected reporters in the industry
with STAT+ reporters and leading industry experts in our STAT+ Conversations series
hosted by STAT+, plus early-bird access and discounts to industry events around the country
get delivered to your inbox to brief you on the most important industry news of the day
like our CRISPR Trackr and Drug Pricing Policy Tracker
from some of the nation’s most trusted and well-connected journalists
hosted by STAT+, plus early access and discounts to can’t-miss industry gatherings
delivered to your inbox with the latest market-moving news and insights
that help you stay up to date with the latest research and developments
on the technologies, personalities, power brokers, and political forces driving changes in life science
plus early access and discounts to industry gatherings
delivered straight to your inbox with the latest industry news
that help you stay up to date with industry research and developments
By Tara Bannow Dec. 14, 2022
Almost 90% of the health care companies deemed to be under financial stress by a leading credit rating agency are owned by private equity, a stark indicator of the toll financial investors have taken on a vital sector.
The striking finding is part of a new Moody’s Investors Service report released this week that shows broad turbulence throughout an industry weakened by private equity’s practice of loading companies with debt, making them less resilient to challenges like Covid-19, rising interest rates, litigation, or changes from a new federal law against surprise billing. Among the 193 North American health care companies Moody’s rates, the agency had placed almost 18% at or below its rating that indicates credit stress, B3 negative, as of Nov. 30. That’s compared with just 4% at the end of 2015.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
Hospitals and Insurance Reporter
Tara covers hospitals, providers, and insurers.
Congress
Coronavirus
finance
hospitals
Medicare
physicians
STAT+
This name will appear with your comment
There was an error saving your display name. Please check and try again.
advertisement
Reporting from the frontiers of health and medicine
You’ve been selected! Subscribe to STAT+ for less than $2 per day
Unlimited access to essential biotech, medicine, and life sciences journalism
Subscribe to STAT+ for less than $2 per day
Unlimited access to the health care news and insights you need